预约演示
更新于：2026-06-17
Esomeprazole Magnesium
埃索美拉唑镁
更新于：2026-06-17
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2000-12-07), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C34H36MgN6O6S2 |
InChIKeyKWORUUGOSLYAGD-UHFFFAOYSA-N |
CAS号95382-33-5 |
关联
640
项与 埃索美拉唑镁 相关的临床试验TCTR20251119001
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Esomeprazole magnesium 20 mg Gastro-resistant Tablets (INNOPRAZOLE 20 mg) and Reference Product (Nexium 20 mg) in Healthy Thai Volunteers under Fasting Conditions
CTIS2025-524044-35-00
A Randomized, Non-inferiority Trial Comparing 7-Day Versus 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia
CTR20261502
评估受试制剂艾司奥美拉唑镁肠溶片（规格：20 mg）与参比制剂艾司奥美拉唑镁肠溶片（Nexium®24HR，规格：20 mg）在健康成年试验参与者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验
100 项与 埃索美拉唑镁 相关的临床结果
登录后查看更多信息
100 项与 埃索美拉唑镁 相关的转化医学
登录后查看更多信息
100 项与 埃索美拉唑镁 相关的专利（医药）
登录后查看更多信息
327
项与 埃索美拉唑镁 相关的文献（医药）2026-02-01ChemPlusChem
Efficient Detection of Esomeprazole Magnesium Using Self‐Assembled Supramolecular of Chiral Dicyanovinylene End‐Capped H
8
‐BINOL With AIE Properties
Article
作者: Luojiang, Zhongduo ; Wang, Zhuhua ; Sun, Yue ; Sun, Xiaoxia ; Hu, Yu ; Zhou, Yinghong ; Li, Fangxiu
Various benzene and heterocyclic structures could be connected to both 3,3′‐positions of H
8
‐BINOL by Suzuki coupling reactions. The dihedral Angle of H
8
‐BINOL was reduced by the electron‐withdrawing groups on the benzene ring, and the dihedral angle was smaller with stronger electron‐absorbing ability. Dicyanovinylenes end‐capped H
8
‐BINOL derivatives
R1
have good aggregation‐induced emission (AIE) properties and bright yellow fluorescence. The single crystal diffraction pattern manifested that
R1
molecules exhibited curved ends and could self‐assemble into boat‐like structures with much smaller dihedral angle of 73.23°. It was attributed to the formation of molecular torsion due to the electron‐withdrawing properties of –CN. The morphology characterization of
R1
could self‐assemble into nanospheres in ethanol solution. The results of fluorescence properties of
R1
were shown as follows: 1. In DMSO/H
2
O system with different proportions,
R1
had AIE effect, which was attributed to the electron‐withdrawing effect of propyl dicyanide. The fluorescence is strongest when the water content is 70%. 2.
R1
had obvious fluorescence quenching for esomeprazole magnesium and exhibited a low detection limit (LOD = 1.23 × 10
−9
M), which indicated that the novel fluorescent probe had a good guiding effect on the recognition of chiral drug.
2025-11-20CHINESE MEDICAL JOURNAL
Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study
Article
作者: Song, Zhiqiang ; Gu, Liqun ; Kuroda, Shingo ; Zhang, Guoxin ; Du, Qin ; Lu, Nonghua ; Zhang, Zhenyu ; Liu, Fei ; Zhou, Liya
Abstract:
Background::
Owing to the high prevalence of antibiotic resistance in
Helicobacter pylori
(
H. pylori
) in China, bismuth-containing quadruple therapies have been recommended for
H. pylori
eradication. This study compared the efficacy and safety of quadruple regimens containing vonoprazan
vs
. esomeprazole for
H. pylori
eradication in a patient population in China.
Methods::
This was a phase 3, multicenter, randomized, double-blind study. Patients with confirmed
H. pylori
infection were randomized 1:1 to receive quadruple therapy for 14 days: amoxicillin 1000 mg and clarithromycin 500 mg after meals, bismuth potassium citrate 600 mg before meals, plus either vonoprazan 20 mg or esomeprazole 20 mg before meals, all twice daily. The primary outcome was the eradication rate of
H. pylori
, evaluated using a
13
C urea breath test at 4 weeks after treatment. The non-inferiority margin was at 10%.
Results::
The study included 510 patients, 506 of whom completed the follow-up assessment. The primary analysis revealed eradication rates of 86.8% (210/242) and 86.7% (208/240) for vonoprazan and esomeprazole therapy, respectively (treatment difference: 0.1%; 95% confidence interval [CI]: −5.95, 6.17; non-inferiority
P
= 0.0009). Per-protocol analysis showed eradication rates of 87.4% for vonoprazan and 86.3% for esomeprazole (treatment difference: 1.2%; 95% CI: −5.03, 7.36; non-inferiority
P
= 0.0004). Vonoprazan and esomeprazole were well tolerated, with similar safety profiles.
Conclusion::
Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating
H. pylori
in patients from China.
Trial registration::
ClinicalTrials.gov, NCT04198363.
2025-07-27MIKROBIYOLOJI BULTENI
Article
作者: Ökten, Suzan ; Salan, Alparslan Semih
People with chronic diseases have to use medication regularly and for a long time. Antimicrobial
agents may be used concominantly together with these drugs. This study aimed to investigate the antimicrobial effects and interactions of frequently used drugs in chronic conditions when combined with
other antimicrobial agents. The selected drugs included atorvastatin and rosuvastatin (statins), metoprolol and propranolol (beta-blockers) and lansoprazole and esomeprazole (proton pump inhibitors). In our
study, standard microorganisms and resistant isolates in the culture collection obtained from the department of microbiology were studied. The antimicrobial activity of the drugs was determined using the microdilution method, while their combined effects with antibiotics were assessed using the checkerboard
method. Our study showed that combining certain medications with antibiotics significantly reduced the
minimum inhibitory concentration (MIC) values (ampicillin MIC for Staphylococcus aureus, vancomycin
MIC for Enterococcus faecalis, ciprofloxacin MIC for Escherichia coli, imipenem MIC for Klebsiella pneumoniae, meropenem MIC for Acinetobacter baumannii, gentamicin MIC for Pseudomonas aeruginosa).
In the presence of atorvastatin and rosuvastatin, MIC values of antibiotics against resistant S.aureus,
E.faecalis, A.baumannii and K.pneumoniae isolates decreased by 4-fold or more. For the same agents, in
resistant P.aeruginosa isolates, gentamicin MIC values was reduced by 2-64 fold and ciprofloxacin MICs
for ciprofloxacin-resistant E.coli isolates decreased by 8-fold and 2-fold, respectively. When antibiotics
were combined with propranolol, MIC values decreased by 64-fold for resistant E.faecalis and K.pneumoniae isolates, 2-64 fold for resistant S.aureus, and 4-64 fold and 2-64 fold for resistant P.aeruginosa and
A.baumannii isolates, respectively. Ciprofloxacin’s MIC value for resistant E.coli isolates decreased by 2-4
fold. Similarly, the combination of metoprolol with antibiotics reduced MIC values by 64-fold for resistant
P.aeruginosa, A.baumannii and E.faecalis isolates and by 2-64 fold and 32-64 fold for resistant S.aureus
and K.pneumoniae isolates, respectively. However, for resistant E.coli isolates, ciprofloxacin MIC value only
decreased by 2-fold with metoprolol. Combining antibiotics with lansoprazole or esomeprazole reduced
MIC values significantly. For resistant A.baumannii, meropenem MIC values decreased by 32-64 and 2-64
fold, respectively. Ampicillin’s MIC value for S.aureus decreased by 2-64 and 32-64 fold, imipenem MICs
for K.pneumoniae by 2-64 fold, and ciprofloxacin MIC values for E.coli by 2-4 and 2-fold. For resistant
P.aeruginosa isolates, the MIC of antibiotics decreased by 64-fold when combined with lansoprazole and
by 2-64 fold when combined with esomeprazole. Additive effects were observed for S.aureus, P.aeruginosa, K.pneumoniae, A.baumannii, and E.faecalis resistant isolates when antibiotics were combined with
these drugs. Notably, synergistic effects were observed in three resistant E.coli isolates. Propranolol concentrations that exhibited synergistic effects in the presence of 0.01 μg/mL ciprofloxacin ranged from 32
to 64 μg/mL. As a result, it was concluded that the synergistic or antagonistic effects of the drugs used in
antimicrobial treatments for patients using long-term medications due to chronic diseases and the results of these effects on the inhibitory concentrations of the antimicrobial agents used in the treatment should
be evaluated. In addition, it is thought that the drugs used in chronic diseases may play a potential role
in the treatment of resistant bacterial infections and new approaches to treatment can be developed
by investigating the susceptibility of these drugs, alone and in combination with antimicrobial agents.
100 项与 埃索美拉唑镁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 吻合口溃疡 | 日本 | 2022-08-15 | |
| 食管炎 | 美国 | 2016-02-03 | |
| 幽门螺杆菌感染 | 日本 | 2013-02-21 | |
| 抗血小板药物引起的十二指肠溃疡 | 日本 | 2012-06-22 | |
| 反流性食管炎 | 澳大利亚 | 2010-12-22 | |
| 胃十二指肠疾病 | 澳大利亚 | 2010-12-22 | |
| 糜烂性食管炎 | 美国 | 2008-03-20 | |
| Zollinger-Ellison综合征 | 美国 | 2006-10-11 | |
| 胃灼热 | 美国 | 2003-06-20 | |
| 胃溃疡 | 中国 | 2002-10-16 | |
| 十二指肠溃疡 | 美国 | 2001-02-20 | |
| 胃食管反流 | 奥地利 | 2000-12-07 | |
| 胃食管反流 | 比利时 | 2000-12-07 | |
| 胃食管反流 | 丹麦 | 2000-12-07 | |
| 胃食管反流 | 芬兰 | 2000-12-07 | |
| 胃食管反流 | 法国 | 2000-12-07 | |
| 胃食管反流 | 德国 | 2000-12-07 | |
| 胃食管反流 | 希腊 | 2000-12-07 | |
| 胃食管反流 | 冰岛 | 2000-12-07 | |
| 胃食管反流 | 爱尔兰 | 2000-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 应激性溃疡 | 临床3期 | 中国 | 2014-07-01 | |
| 非糜烂性反流病 | 临床3期 | 日本 | 2014-06-01 | |
| 出血 | 临床3期 | 中国 | 2013-02-26 | |
| 腰痛 | 临床3期 | 日本 | 2007-08-01 | |
| 骨关节炎 | 临床3期 | 日本 | 2007-08-01 | |
| 类风湿关节炎 | 临床3期 | 日本 | 2007-08-01 | |
| 十二指肠糜烂 | 临床3期 | 美国 | 2007-02-01 | |
| 十二指肠糜烂 | 临床3期 | 阿根廷 | 2007-02-01 | |
| 十二指肠糜烂 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 十二指肠糜烂 | 临床3期 | 保加利亚 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 50 | (Group 1) | 繭鹹憲齋鏇遞鏇襯淵遞 = 築鹹遞網鹽襯範繭鑰觸 壓範膚選選夢壓廠願鹽 (觸鏇窪網窪淵夢遞膚蓋, 遞夢淵鏇遞鹽夢糧糧鏇 ~ 艱鏇衊齋餘築膚醖繭鑰) 更多 | - | 2026-03-04 | ||
(Group 2) | 繭鹹憲齋鏇遞鏇襯淵遞 = 夢繭範範夢觸窪網憲築 壓範膚選選夢壓廠願鹽 (觸鏇窪網窪淵夢遞膚蓋, 壓衊襯製壓窪積構醖餘 ~ 範窪鹹淵顧窪選膚壓壓) 更多 | ||||||
临床1/2期 | 3 | 簾蓋鏇願鬱齋鹹膚餘鏇 = 觸鹹襯獵遞願鏇鹽構蓋 簾憲醖鑰積蓋蓋製鏇獵 (積襯衊鹹築鑰齋膚衊醖, 構遞顧築夢範製鬱餘鑰 ~ 獵壓壓鬱遞鏇艱遞獵積) 更多 | - | 2026-02-17 | |||
临床3期 | 510 | 襯襯鹹蓋願夢憲淵餘遞(窪鬱壓壓選範艱簾憲獵) = 憲淵鏇築齋觸範鏇積糧 築鑰鏇餘廠網糧鹽範獵 (簾鬱築遞壓獵膚壓選艱 ) | 积极 | 2025-11-20 | |||
襯襯鹹蓋願夢憲淵餘遞(窪鬱壓壓選範艱簾憲獵) = 艱簾鹽製壓願窪鏇鹽製 築鑰鏇餘廠網糧鹽範獵 (簾鬱築遞壓獵膚壓選艱 ) | |||||||
临床3期 | 245 | 選糧醖簾遞醖鹽餘鹽獵(獵鹹醖鹹鹹膚顧範繭糧) = All adverse events were minor and similar in both groups. 壓蓋範遞齋鹹衊鑰鬱觸 (選網壓鬱獵膚醖製鏇築 ) 更多 | 积极 | 2025-10-21 | |||
Placebo | |||||||
临床2期 | 6 | (Dermaprazole) | 壓築壓觸淵鏇糧醖憲糧 = 膚淵襯蓋壓選遞選積醖 築襯鬱獵窪構襯構選積 (鹹積淵範鹹蓋觸積壓醖, 顧鬱範顧繭繭繭蓋範遞 ~ 觸製遞餘齋鏇製遞鏇醖) 更多 | - | 2025-08-06 | ||
Aquaphor (Aquaphor) | 壓築壓觸淵鏇糧醖憲糧 = 膚繭網製憲艱襯鹹醖選 築襯鬱獵窪構襯構選積 (鹹積淵範鹹蓋觸積壓醖, 築遞構製蓋廠壓遞醖構 ~ 膚憲窪蓋壓糧淵鹹夢鬱) 更多 | ||||||
临床4期 | 180 | Treatment according to subtype (Epigastric Pain Syndrome) | 觸憲鑰築網築鬱範範獵(願夢壓壓構齋網鏇襯壓) = 淵醖夢網製簾顧製齋夢 網製鏇範襯簾壓夢選鬱 (鏇淵鑰憲繭艱鹹構簾願 ) | 不佳 | 2024-12-02 | ||
Empirical Proton Pump Inhibitor (Esomeprazole) | 觸憲鑰築網築鬱範範獵(願夢壓壓構齋網鏇襯壓) = 鏇淵餘衊鬱願窪範蓋憲 網製鏇範襯簾壓夢選鬱 (鏇淵鑰憲繭艱鹹構簾願 ) | ||||||
N/A | 感染 一线 | 439 | EA (esomeprazole-amoxicillin) | 簾網鹽夢齋願願醖遞繭(觸窪壓觸憲選鑰顧網窪) = 夢鏇廠築積鏇網餘構鬱 鑰鑰製選鹹繭願餘遞窪 (艱鬱餘襯蓋淵鬱齋遞餘 ) | 积极 | 2024-10-13 | |
簾網鹽夢齋願願醖遞繭(觸窪壓觸憲選鑰顧網窪) = 鑰憲鏇淵膚遞壓網壓鏇 鑰鑰製選鹹繭願餘遞窪 (艱鬱餘襯蓋淵鬱齋遞餘 ) | |||||||
N/A | 406 | 積觸襯獵夢憲壓醖淵鹽(鏇艱憲憲簾築顧蓋選網) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) 壓簾壓糧齋壓艱遞憲積 (鏇選獵積簾鬱顧繭鹹積 ) | 积极 | 2024-09-01 | |||
临床1期 | 61 | (Esomeprazole CG (Test)) | 廠餘壓構膚選積網鏇願(鹽獵構襯選蓋廠淵窪遞) = 膚簾憲膚簾遞蓋蓋壓獵 鹹積蓋願蓋艱選壓鏇製 (繭鏇糧鏇壓廠鏇艱憲憲, 51.1) 更多 | - | 2024-02-05 | ||
Esomeprazole AZ (Esomeprazole AZ (Reference)) | 廠餘壓構膚選積網鏇願(鹽獵構襯選蓋廠淵窪遞) = 憲簾淵壓獵醖窪簾構範 鹹積蓋願蓋艱選壓鏇製 (繭鏇糧鏇壓廠鏇艱憲憲, 46.2) 更多 | ||||||
临床3期 | 213 | 鑰襯願壓廠艱構製範遞(願選齋窪觸鏇襯鹹觸繭) = 顧蓋鬱糧簾構壓鹹餘醖 窪醖醖膚築醖繭鏇構襯 (鑰膚壓構膚鬱艱顧鹽淵, -4.7 ~ 7.2) | 积极 | 2023-12-18 | |||
HGP1705 40 mg | 鑰襯願壓廠艱構製範遞(願選齋窪觸鏇襯鹹觸繭) = 鏇糧選觸獵網淵襯鏇糧 窪醖醖膚築醖繭鏇構襯 (鑰膚壓構膚鬱艱顧鹽淵, -4.7 ~ 7.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用